Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
MMACKD
The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease
2 other identifiers
observational
300
1 country
1
Brief Summary
The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 30, 2011
CompletedStudy Start
First participant enrolled
October 1, 2011
CompletedFirst Posted
Study publicly available on registry
October 24, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedFebruary 23, 2015
February 1, 2015
4.6 years
September 30, 2011
February 20, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease
Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.
two years
Secondary Outcomes (1)
Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease
two years
Study Arms (3)
Diabetic nephropathy
Diabetic nephropathy in patients with type 2 diabetes
chronic glomerulonephritis
chronic glomerulonephritis in patients without diabetes mellitus
controls
participants without diabetic nephropathy and chronic glomerulonephritis
Eligibility Criteria
Patients from University Hospital AHEPA
You may qualify if:
- Chronic kidney disease
- Diabetes mellitus type 2
You may not qualify if:
- Malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aristotle University Of Thessalonikilead
- AHEPA University Hospitalcollaborator
Study Sites (1)
AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki
Thessaloniki, Greece
Biospecimen
serum and vessels
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Grigorios G. Dimas, MD
AHEPA University Hospital,Medical School of Aristotle University of Thessaloniki
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor/PhD Candidate
Study Record Dates
First Submitted
September 30, 2011
First Posted
October 24, 2011
Study Start
October 1, 2011
Primary Completion
May 1, 2016
Study Completion
May 1, 2016
Last Updated
February 23, 2015
Record last verified: 2015-02